Press Releases May 7, 2026 07:01 AM

Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026

Invivyd schedules Q1 2026 financial results call and corporate update for May 14, 2026

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
IVVD

Invivyd, a US-based biopharmaceutical company focused on antiviral monoclonal antibodies, announced it will hold a webcast conference call on May 14, 2026 to discuss its first quarter financials and provide a corporate update. The company recently received FDA emergency use authorization for a monoclonal antibody targeting SARS-CoV-2, underscoring its focus on combating serious viral infectious diseases.

Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026
IVVD
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Invivyd to report Q1 2026 financial results and corporate updates on May 14, 2026.
  • Company obtained FDA emergency use authorization for a SARS-CoV-2 monoclonal antibody in March 2024.
  • Invivyd specializes in developing antibody therapies against serious viral infections using a proprietary technology platform.

NEW HAVEN, Conn., May 07, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, May 14, 2026 at 8:30 a.m. ET to discuss its first quarter 2026 financial results and provide a corporate update.  

Interested parties can register for the webcast via this link. Analysts wishing to participate in the question-and-answer session should use this link. A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.

About Invivyd 

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.

Contacts: 
Media Relations 
(781) 208-0160 
media@invivyd.com 

Investor Relations 
(781) 208-1747 
investors@invivyd.com 


Risks

  • Uncertainties around future financial performance revealed in Q1 results could impact stock.
  • Dependence on regulatory approvals and market acceptance of antibody therapies.
  • Competitive pressures in the biopharmaceutical sector targeting viral infectious diseases.

More from Press Releases

PAVS Announces Pricing of a $10 Million Registered Direct Offering of Class A Ordinary Shares and Pre-Funded Warrants Jun 15, 2026 Rogers Donates $1 Million to 2026 Rogers Charity Classic Jun 15, 2026 Rogers Brings Blue Jays Spirit to Calgary with New Ballpark Experience at Rogers Charity Classic Jun 15, 2026 Correction: Quantum Cyber Executes Exclusive Quantum Antenna License Agreement, Positoning the Quantum Technology Layer at the Core of Its Defense Platform Jun 15, 2026 PatentVest to Present at Planet MicroCap Las Vegas on June 17 Jun 15, 2026